{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:46:35Z","timestamp":1775144795134,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018707","name":"European Commission Reforming and enhancing the European Research and Innovation system","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["226137\/Z\/22\/Z"],"award-info":[{"award-number":["226137\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","award":["PRF 23-47"],"award-info":[{"award-number":["PRF 23-47"]}],"id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016962","name":"Department of Science and Innovation, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016962","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Structure"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.str.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:53:51Z","timestamp":1770220431000},"page":"552-561.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Defining the mechanism of cross-reactivity for a SARS-CoV-2 Beta-elicited antibody toward omicron sub-lineages"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-0415","authenticated-orcid":false,"given":"Frances","family":"Ayres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bronwen","family":"Lambson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nonhlanhla N.","family":"Mkhize","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zanele","family":"Makhado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Mhlanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolph","family":"Serage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penny L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos Kurt","family":"Wibmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4269-9281","authenticated-orcid":false,"given":"Thandeka","family":"Moyo-Gwete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.str.2026.01.006_bib1","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","article-title":"Monoclonal antibody therapies against SARS-CoV-2","volume":"22","author":"Focosi","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.str.2026.01.006_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010465","article-title":"A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant","volume":"18","author":"Hingankar","year":"2022","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.str.2026.01.006_bib3","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00558-22","article-title":"Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus variants","volume":"96","author":"Moyo-Gwete","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2026.01.006_bib4","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1126\/science.abm5835","article-title":"SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies","volume":"375","author":"Reincke","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.str.2026.01.006_bib5","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.immuni.2022.03.019","article-title":"A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2","volume":"55","author":"Wang","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.str.2026.01.006_bib6","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.chom.2022.03.029","article-title":"SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals","volume":"30","author":"Richardson","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.str.2026.01.006_bib7","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","article-title":"Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies","volume":"182","author":"Barnes","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.str.2026.01.006_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.str.2026.01.006_bib9","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.cell.2021.02.032","article-title":"The antigenic anatomy of SARS-CoV-2 receptor binding domain","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.str.2026.01.006_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.006_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.str.2026.01.006_bib12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-022-04464-z","article-title":"ACE2 binding is an ancestral and evolvable trait of sarbecoviruses","volume":"603","author":"Starr","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.006_bib13","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","article-title":"Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology","volume":"183","author":"Piccoli","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.str.2026.01.006_bib14","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.str.2026.01.006_bib15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.006_bib16","article-title":"SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity","volume":"3","author":"Richardson","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.str.2026.01.006_bib17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41586-021-03471-w","article-title":"Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma","volume":"593","author":"Cele","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.006_bib18","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMc2104192","article-title":"Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)","volume":"384","author":"Moyo-Gwete","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.str.2026.01.006_bib19","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1038\/s41598-025-89940-y","article-title":"Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern","volume":"15","author":"Bhiman","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.str.2026.01.006_bib20","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/s41467-021-24435-8","article-title":"Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies","volume":"12","author":"Greaney","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.str.2026.01.006_bib21","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.str.2026.01.006_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.abm8143","article-title":"Antibody-mediated broad sarbecovirus neutralization through the ACE2 molecular mimicry","volume":"375","author":"Park","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.str.2026.01.006_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","article-title":"Human neutralizing antibodies elicited by SARS-CoV-2 infection","volume":"584","author":"Ju","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.006_bib24","article-title":"Structural basis of Omicron neutralization by affinity-matured public antibodies","author":"Sheward","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.str.2026.01.006_bib25","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","article-title":"Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift","volume":"602","author":"Cameroni","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.006_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111335","article-title":"A key F27I substitution within HCDR1 facilitates the rapid maturation of P2C-1F11-like neutralizing antibodies in a SARS-CoV-2-infected donor","volume":"40","author":"Wang","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.str.2026.01.006_bib27","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/s41467-021-24514-w","article-title":"Potent and protective IGHV3-53\/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.str.2026.01.006_bib52","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0022-2836(73)90011-9","article-title":"Environment and exposure to solvent of protein atoms. Lysozyme and insulin","volume":"79","author":"Shrake","year":"1973","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.str.2026.01.006_bib34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/s41586-023-06750-w","article-title":"Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike","volume":"624","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.006_bib35","doi-asserted-by":"crossref","first-page":"7196","DOI":"10.1016\/j.cell.2024.09.026","article-title":"A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification","volume":"187","author":"Rosen","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.str.2026.01.006_bib36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1126\/science.abh2315","article-title":"Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study","volume":"374","author":"Hastie","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.str.2026.01.006_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105354","article-title":"Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants","volume":"108","author":"Luo","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.str.2026.01.006_bib38","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1126\/science.abd0827","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.str.2026.01.006_bib39","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","article-title":"A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2","volume":"584","author":"Shi","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.006_bib40","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.abh1139","article-title":"Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants","volume":"373","author":"Yuan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.str.2026.01.006_bib41","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S1473-3099(23)00555-8","article-title":"Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6","volume":"23","author":"Wang","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.str.2026.01.006_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00119-21","article-title":"Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil","volume":"95","author":"Voloch","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2026.01.006_bib43","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.abf9302","article-title":"Prospective mapping of the viral mutations that escape antibodies used to treat COVID-19","volume":"371","author":"Starr","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.str.2026.01.006_bib44","article-title":"Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.str.2026.01.006_bib45","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.006_bib46","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","article-title":"Considerable escape of SARS-CoV-2 Omicron to antibody neutralization","volume":"602","author":"Planas","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.str.2026.01.006_bib47","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1126\/science.abd2321","article-title":"Structural basis of a shared antibody response to SARS-CoV-2","volume":"369","author":"Yuan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.str.2026.01.006_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/v16010003","article-title":"The Era of the FLips: How Spike Mutations L455F and F456L (and A475V) Are Shaping SARS-CoV-2 Evolution","volume":"16","author":"Focosi","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.str.2026.01.006_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011868","article-title":"Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding","volume":"19","author":"Jian","year":"2023","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.str.2026.01.006_bib50","article-title":"Virological characteristics of the SARS-CoV-2 KP.2 variant","volume":"24","author":"Kaku","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.str.2026.01.006_bib51","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00678-24","article-title":"SARS-CoV-2 BA.4\/5 infection triggers more cross-reactive Fc\u03b3RIIIa signaling and neutralization than BA.1, in the context of hybrid immunity","volume":"98","author":"Richardson","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.str.2026.01.006_bib28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/pro.4224","article-title":"DIALS as a toolkit","volume":"31","author":"Winter","year":"2022","journal-title":"Protein Sci."},{"key":"10.1016\/j.str.2026.01.006_bib29","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.str.2026.01.006_bib30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2026.01.006_bib53","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.21105\/joss.03773","article-title":"Nextclade: clade assignment, mutation calling and quality control for viral genomes","volume":"6","author":"Aksamentov","year":"2021","journal-title":"J. Open Source Softw."},{"key":"10.1016\/j.str.2026.01.006_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.str.2026.01.006_bib32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2023.12.026","article-title":"Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants","volume":"187","author":"Qu","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.str.2026.01.006_bib33","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1038\/s41596-021-00536-y","article-title":"Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays","volume":"16","author":"Bewley","year":"2021","journal-title":"Nat. Protoc."}],"container-title":["Structure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969212626000080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969212626000080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T14:48:06Z","timestamp":1775141286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969212626000080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0969212626000080"],"URL":"https:\/\/doi.org\/10.1016\/j.str.2026.01.006","relation":{},"ISSN":["0969-2126"],"issn-type":[{"value":"0969-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Defining the mechanism of cross-reactivity for a SARS-CoV-2 Beta-elicited antibody toward omicron sub-lineages","name":"articletitle","label":"Article Title"},{"value":"Structure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.str.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}